NCT04510896 is a NA clinical trial of InheRET in Hereditary Cancer-Predisposing Syndrome, sponsored by InheRET, Inc.

Who is sponsoring NCT04510896?

NCT04510896 is sponsored by InheRET, Inc.

What drugs are being tested in NCT04510896?

Interventions in NCT04510896: InheRET, Patient Acceptance, Physician Acceptance Survey.

What condition does NCT04510896 study?

NCT04510896 studies Hereditary Cancer-Predisposing Syndrome.

Is NCT04510896 still recruiting?

NCT04510896 is currently status unknown. Last updated 30 July 2021.

Last reviewed 2021-07-30 · How we verify

NCT04510896

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inherited Risk Evaluation Tool (InheRET): Identifying Patients at Increased Risk for Hereditary Disease

Status unknown NA Last updated 30 July 2021

What this trial tests

NA trial testing InheRET in Hereditary Cancer-Predisposing Syndrome in 2,232 participants. Status unknown.

Timeline

1 September 2020

Primary endpoint
30 June 2022

31 August 2022

Quick facts

Lead sponsor	InheRET, Inc
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	2,232
Start date	1 September 2020
Primary completion	30 June 2022
Estimated completion	31 August 2022
Sites	4 locations across United States

Drugs / interventions tested

InheRET
Patient Acceptance
Physician Acceptance Survey

Conditions studied

Hereditary Cancer-Predisposing Syndrome — all drugs for Hereditary Cancer-Predisposing Syndrome →

Sponsor

InheRET, Inc

Who can join

18 and older, any sex, with Hereditary Cancer-Predisposing Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the impact InheRET™, an online family history gathering and risk assessment reporting tool, has on facilitating National Comprehensive Cancer Network(NCCN) guideline compliant referrals for cancer genetic counseling/genetic evaluation by decreasing and/or removing the barriers of 1) time-consuming in-clinic 3-generation family history collection, and 2) interpretation of the family and personal history in light of current NCCN guidelines. Identifying individuals at increased risk for cancer has been shown to decrease morbidity and mortality in multiple clinical settings. Investigators hypothesize that InheRET will prove to be accurate, efficient, and accessible, and that its use will improve identification of individuals at risk for inherited susceptibility to cancer. The investigators propose also that using this tool will result in a reduction of inappropriate genetic counseling referrals and reduce unnecessary genetic testing in both primary and specialty care settings. InheRET will allow health care providers to focus resources on individuals at higher risk for developing cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04510896 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by InheRET, Inc
Last refreshed: 30 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04510896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing